Shanxi Yabao Pharmaceutical Group and its subsidiaries are engaged in the manufacture and sale of medicine raw materials, injections, tablets, hard gelatin capsules, granules, tea medicinal preparations, oral liquids, grease, health care products, medical supplies, medicinal packing materials, and plastic products; plant and processing of Chinese medicine; research and development of Chinese and western medicine; and importing and exporting self-produced goods. Co.'s major products include Dinggui Erqi Tie, Zhenju Jiangya Pian, Troxerutin Tablets, Compound Reserpin Tables and Nimodipine Tablets. Co. carries out its business predominantly in the People's Republic of China.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.